- Home
- TALKW vs MREO Comparison
TALKW vs MREO Comparison
Compare TALKW & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TALKW | MREO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United Kingdom |
| Employees | 521 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TALKW | MREO |
|---|---|---|
| Price | $0.04 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 64.2K | ★ 2.6M |
| Earning Date | 02-20-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,291,000.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $163.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.20 | $1.47 |
| 52 Week High | $0.24 | $3.88 |
Technical Indicators
Market Signals| Indicator | TALKW | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 63.13 |
| Support Level | $0.04 | $1.89 |
| Resistance Level | $0.07 | $2.37 |
| Average True Range (ATR) | 0.01 | 0.18 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 32.24 | 87.30 |
Price Performance
Historical ComparisonAbout TALKW Talkspace Inc. Warrant
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).